The Trump administration isn’t planning to impose tariffs on generic drugs, narrowing the scope of pharmaceutical levies, The Wall Street Journal’s Gavin Bade reports. The decision reverses a campaign pledge and follows internal debate regarding potential price increases or drug shortages from tariffs. “The administration is not actively discussing imposing Section 232 tariffs against generic pharmaceuticals,” White House spokesman Kush Desai said in a statement. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Balanced Outlook for Johnson & Johnson: Hold Rating Amid Stable Revenue and Slight EPS Decline
- Protagonist Therapeutics price target raised to $74 from $62 at Clear Street
- IBM partners with Anthropic, Dell boosts long-term view: Morning Buzz
- Jury awards $966M in talc verdict against Johnson & Johnson, Law.com reports
- Johnson & Johnson’s icotrokinra meets primary endpoint in ulcerative colitis